Table 5.
Prevalence of consumption amongst 18–25 year old from Canada, United Kingdom, Australia and New Zealand.
| Other Countries 18-25 | |||||||
|---|---|---|---|---|---|---|---|
| Country | Survey | Age Range (Years) | Years | Measure | Prevalence (%) | % Change | Trend |
| UK (England) | Health Survey for England (Ng Fat et al., 2018) |
18–24 | 2005–2015 | “Nowadays”a | T: 85–76 | −9.0 | ↘ |
| Australia | Australian National Health Survey (Australian Bureau of Statistics, 2002, 2017–18) | 18–24 | 2001–2017/8 | Past weekb | T: 63.3–48.4 M: 68.3–52.6 F: 58.1–44.0 |
−14.9 −15.4 −14.1 |
↘ |
| Past yearb | T: 90.7–83.8 M: 91.6–84.4 F: 90.0–83.3 |
−6.9 −7.2 −6.7 |
↘ | ||||
| Lifetimeb | T: 93.3–88.6 M: 93.5–89.4 F: 93.0–88.0 |
−4.7 −4.1 −5.0 |
↔ | ||||
| National Drug Strategy Household Survey | 18–24 | 2001–2019 (AIHW, 2021) | Past year | T: 90.3–79.2 | −11.1 | ↘ | |
| 2001–2013 (Livingston, 2015) |
Lifetimea | T: 92.5–86.3 | −6.2 | ||||
| New Zealand | New Zealand Health Survey | 18–24 | 2006/7–2018/19 (Ministry of Health, n.d.) | Past year | T: 89.1–85.6 | −3.7 | ↔ |
Key: ↗: Increase of >5.0% between the start and end point provided; ↘: Decrease of >5.0% between the start and end point provided; ↔: Stable – any value with an increase or decrease of ≤5% between the start and end point provided. UK: United Kingdom; T: total; M: male; F: female.
a
Author-calculated value based on data available in the original record.
b
Reported in record as abstention data.